Synopsis of recent research by authors named "Bryan K Chan"
- Bryan K Chan's recent research primarily focuses on the discovery and development of selective small molecule inhibitors targeting specific kinases, such as Hematopoietic Progenitor Kinase 1 (HPK1) and Leucine-Rich Repeat Kinase 2 (LRRK2), which are vital in cancer immunotherapy and neurodegenerative diseases like Parkinson's.
- His studies demonstrate that inhibiting HPK1 can enhance T-cell activation, potentially improving the efficacy of immunotherapy treatments, while LRRK2 inhibitors show promise as a therapeutic strategy for mitigating the effects of Parkinson's Disease.
- Chan's work also includes evaluations of in silico models for predicting drug mutagenicity and the development of structural modifications to enhance the pharmacological properties and selectivity of his discovered inhibitors.
